论文部分内容阅读
市售等渗溴化异丙阿托品(Atrovent)雾化吸入疗法,广泛用于治疗可逆性的气道阻塞性疾病,其中防腐剂氯化苯甲羟氨和乙二胺四乙酸(EDTA)有制菌及稳定剂作用,也偶为发生反常气道痉挛的原因。作者将30例哮喘者随机分别吸入2ml Atrovent 或等渗的无防腐剂的溴化异丙托品雾化溶液,进行双盲对照研究,在45分钟内测定FEV_1。发现1/4哮喘患者吸入Atrovent(含防腐剂)初量4ml 后(即1mg 溴化异丙阿托品),即可发作支气管痉挛,FEV_1下降超过基础值20%以上。如吸入无防腐剂的溴化异丙托品则仅扩张支气管,而不产生支气管痉挛,其扩张支气管效应也较Atrovent 迅速且显著,最大治疗效应FEV_1增加29.2%,而Atrovent 为18.5%.显然Atrovent 内的防腐剂产生的支气管痉
Commercially available isotonic Atrovent nebulization is widely used in the treatment of reversible airway obstructive diseases, where the preservatives of CBZ and ethylenediaminetetraacetic acid (EDTA) Bacteria and stabilizers, but also occasionally cause abnormal airway spasm. The authors randomized 30 asthmatics to inhalation of 2 ml of Atrovent or isotonic non-preservative ipratropium nebulized solution, respectively, for a double-blind controlled study to determine FEV_1 in 45 minutes. One quarter of patients with asthma were found to have bronchospasm after inhaling the initial 4 ml of Atrovent (with preservatives) (ie, 1 mg of isopropyla bromide), and FEV 1 decreased more than 20% of baseline. If inhaled without preservatives ipratropium bromide only bronchial expansion, without bronchospasm, the expansion of bronchial effects than Atrovent rapid and significant, the maximum therapeutic effect of FEV_1 increased 29.2%, while Atrovent was 18.5%. Clearly Atrovent Preservatives within the bronchospasm produced